Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

NCT01534078 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Adriamycin, vinblastine, and dacarbazine

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]